Regeneron stock soars on successful trial news
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Regeneron stock skyrocketed Thursday on news that an 8-milligram dose of an eye drug successfully treated patients with diabetic macular edema and wet age-related macular degeneration in two
pivotal trials. Regeneron Pharmaceuticals (REGN) announced that the studies showed that 8-mg 12- and 16-week dosing regimens of the generic form of its Eylea drug, called aflibercept,
"achieved non-inferiority in vision gains…